litlas
Log inCreate account

C. Boni

Active 1983–2018

36
Papers
20,646
Citations
36
h-index
36
i10-index

Citations

Citations per year for C. Boni1984: 1 citations1985: 2 citations1988: 1 citations1989: 1 citations1990: 2 citations1992: 2 citations1993: 3 citations1994: 1 citations1995: 6 citations1996: 5 citations1997: 1 citations1998: 10 citations1999: 22 citations2000: 21 citations2001: 35 citations2002: 64 citations2003: 91 citations2004: 119 citations2005: 158 citations2006: 139 citations2007: 165 citations2008: 144 citations2009: 150 citations2010: 151 citations2011: 166 citations2012: 126 citations2013: 160 citations2014: 198 citations2015: 182 citations2016: 157 citations2017: 166 citations2018: 123 citations2019: 461 citations2020: 397 citations2021: 346 citations2022: 242 citations2023: 148 citations2024: 232 citations2025: 98 citations2026: 4 citations1986–1987: no citations, so these years are not shown1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,426 citing papers, 21.5% of this breakdownItaly: 558 citing papers, 8.4% of this breakdownChina: 469 citing papers, 7.1% of this breakdownFrance: 426 citing papers, 6.4% of this breakdownUnited Kingdom: 421 citing papers, 6.4% of this breakdownGermany: 375 citing papers, 5.7% of this breakdownJapan: 327 citing papers, 4.9% of this breakdownSpain: 275 citing papers, 4.1% of this breakdownNetherlands: 195 citing papers, 2.9% of this breakdownBelgium: 176 citing papers, 2.7% of this breakdownCanada: 174 citing papers, 2.6% of this breakdownSouth Korea: 172 citing papers, 2.6% of this breakdown
0%21.5%Other 24.7%

Institutions

Fields

  • Medicine77%
  • Biochemistry, Genetics and Molecular Biology18.7%
  • Immunology and Microbiology0.9%
  • Materials Science0.7%
  • Neuroscience0.5%
  • Engineering0.4%
  • Other1.8%

Topics

  • Colorectal Cancer Treatments and Studies11.2%
  • Colorectal Cancer Surgical Treatments6.3%
  • Gastric Cancer Management and Outcomes4.8%
  • Cancer Treatment and Pharmacology4.1%
  • Hepatocellular Carcinoma Treatment and Prognosis4%
  • Genetic factors in colorectal cancer3.1%
  • Other66.5%

Coauthors

All papers

Open in search
  1. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

    Authors: Thierry André, C. Boni, Lamia Mounedji-Boudiaf, Matilde Navarro, Josep Tabernero, Tamas Hickish, C. Topham, Marta Zaninelli, Philip R. Clingan, John Bridgewater, Isabelle Tabah-Fisch, Aimery de Gramont - New England Journal of Medicine 2004 cited by 3,658

  2. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

    Authors: Thierry André, C. Boni, Matilde Navarro, Josep Tabernero, Tamas Hickish, C. Topham, Andrea Bonetti, Philip R. Clingan, John Bridgewater, Fernando Rivera, Aimery de Gramont - Journal of Clinical Oncology 2009 cited by 2,292

  3. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

    Authors: Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, D. Amoroso, Silvana Chiara, Chiara Carlomagno, C. Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone - New England Journal of Medicine 2014 cited by 1,078

  4. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

    Authors: Eric Van Cutsem, Vladimir Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla, C. Boni, Adriano Rodrigues, M Fodor, Yee Chao, Э К Возный, Marie-Laure Risse, Jaffer A. Ajani - Journal of Clinical Oncology 2006 cited by 1,933

  5. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

    Authors: Aimery de Gramont, Arié Figer, Michel Seymour, M. Homerin, Abdel Hmissi, Jim Cassidy, C. Boni, H. Cortés-Funes, Andrés Cervantes, Gilles Freyer, D. Papamichael, N Le Bail, Christophe Louvet, Daniel Hendler, Filippo de Braud, C. Wilson, F. Morvan, Andrea Bonetti - Journal of Clinical Oncology 2000 cited by 3,820

  6. Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial

    Authors: Christophe Tournigand, Thierry André, Franck Bonnetain, Benoist Chibaudel, Gérard Lledo, Tamas Hickish, Josep Tabernero, C. Boni, Jean‐Baptiste Bachet, Luís Teixeira, Aimery de Gramont - Journal of Clinical Oncology 2012 cited by 390

  7. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial

    Authors: Gianluca Masi, Lisa Salvatore, Luca Boni, Fotios Loupakis, Chiara Cremolini, Lorenzo Fornaro, Marta Schirripa, S. Cupini, C. Barbara, V. Safina, Cristina Granetto, Elena Fea, Lorenzo Antonuzzo, C. Boni, Giacomo Allegrini, S. Chiara, D. Amoroso, Andrea Bonetti, Alfredo Falcone - Annals of Oncology 2015 cited by 169

  8. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

    Authors: Armando Santoro, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean‐Luc Van Laethem, Hans Van Vlierberghe, Jörg Trojan, Frank T. Kolligs, Alan Weiss, Steven A. Miles, Antonio Gasbarrini, Monica Lencioni, Luca Cicalese, Morris Sherman, Cesare Gridelli, Peter Buggisch, Guido Gerken, Roland M. Schmid, C. Boni, Nicola Personeni, Ziad Hassoun, Giovanni Abbadessa, Brian Schwartz, Reinhard von Roemeling, Maria Lamar, Yinpu Chen, Camillo Porta - The Lancet Oncology 2012 cited by 550

  9. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

    Authors: Lucia Del Mastro, Sabino De Placido, Paolo Bruzzi, Michele De Laurentiis, C. Boni, Giovanna Cavazzini, Antonio Durando, Anna Turletti, Cecilia Nisticò, Enrichetta Valle, Ornella Garrone, Fabio Puglisi, Filippo Montemurro, Sandro Barni, Andrea Ardizzoni, Teresa Gamucci, Giuseppe Colantuoni, Mario Giuliano, Adriano Gravina, Paola Papaldo, Claudia Bighin, Giancarlo Bisagni, Valeria Forestieri, Francesco Cognetti - The Lancet 2015 cited by 201

  10. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

    Authors: Eric Van Cutsem, C. Boni, Josep Tabernero, Bartomeu Massutí, Gary Middleton, Faysal Dane, Peter Reichardt, Francisco Pimentel, Allen Lee Cohn, Philippe Follana, Michael Clemens, Alberto Zaniboni, Vladimir Moiseyenko, Mark Harrison, Donald Richards, Hans Prenen, Simon Pernot, Evelyne Ecstein-Fraïsse, Simon Hitier, P. Rougier - Annals of Oncology 2014 cited by 133

  11. Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group

    Authors: Henning T. Mouridsen, Mikhail Gershanovich, Yan Sun, R. Pérez-Carrión, C. Boni, Alain Monnier, Justus Apffelstaedt, Robert E. Smith, H.P. Sleeboom, Fritz Jaenicke, A Płużańska, Magdolna Dank, D. Becquart, P. P. Bapsy, Eeva Salminen, Ray Snyder, Hilary A. Chaudri‐Ross, Raquel Lang, P.J. Wyld, Ajay S. Bhatnagar - Journal of Clinical Oncology 2003 cited by 746

  12. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

    Authors: Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, Giancarlo Bisagni, Grazia Arpino, Maria Giuseppa Sarobba, Ferdinando Riccardi, Antonio Russo, Lucia Del Mastro, Alessio Aligi Cogoni, Francesco Cognetti, Stefania Gori, Jennifer Foglietta, Antonio Frassoldati, D. Amoroso, Lucio Laudadio, Luca Moscetti, Filippo Montemurro, Claudio Verusio, Antônio Bernardo, Vito Lorusso, Adriano Gravina, Gabriella Moretti, Rossella Lauria, Antonella Lai, Carmela Mocerino, Sérgio Rizzo, Francesco Nuzzo, Paolo Carlini, Francesco Perrone, Antonello Accurso, Biagio Agostara, Michele Aieta, Oscar Alabiso, Maria Grazia Alicicco, Dino Amadori, Laura Amaducci, Gianna Amiconi, Giustino Antuzzi, Mara Ardine, Antonio Ardizzoia, Caterina Aversa, Giuseppe Badalamenti, Sandro Barni, Carlo Basurto, Rossana Berardi, Cinzia Bergamasco, Paolo Bidoli, Claudia Bighin, Edoardo Biondi, Giancarlo Bisagni, C. Boni, Karen Borgonovo, Mario Botta, Stefano Bravi, Paolo Bruzzi, Giuseppe Buono, Alfredo Butera, A. Caldara, Giampiero Candeloro, C. Cappelletti, Cinzia Cardalesi, E Carfora, Anna Cariello, Francesco Carrozza, Giacomo Cartenì, Michele Caruso, Virginia Casadei, Cláudia Casanova, L. Castori, Luigi Cavanna, Giovanna Cavazzini, Marina Elena Cazzaniga, Mario Giovanni Chilelli, Paolo Chiodini, Silvia Chiorrini, Fortunato Ciardiello, Mariangela Ciccarese, Saverio Cinieri, Mario Clerico, Mariarosa Coccaro, Mario Comandè, Claudia Corbo, G. Cortino, Stefania Cusenza, Gennaro Daniele, Alfonso Maria D’Arco, G. D'Auria, Claudio Dazzi, Carmine De Angelis, Filippo de Braud, Gianfranco De Feo, A. De Matteis, Michele De Tursi, Anna Di Blasio, Giuseppe Di Lucca, Liberato Di Lullo, Francesca Di Rella, Gianfranco Di Renzo, P. Di Stefano and 128 more - The Lancet Oncology 2018 cited by 88

  13. Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer

    Authors: Umberto Veronesi, G. De Palo, Ettore Marubini, Alfredo Costa, Franca Formelli, Luigi Mariani, Andrea DeCensi, Tiziana Camerini, Marco Rosselli Del Turco, Maria Gaetana Di Mauro, Maria Grazia Muraca, M. Del Vecchio, Carmine Pinto, Giuseppe D’Aiuto, C. Boni, Tiziana Campa, Andrea Magni, Rosalba Miceli, Marjorie Perloff, Winfred F. Malone, Michael B. Sporn - JNCI Journal of the National Cancer Institute 1999 cited by 421

  14. Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

    Authors: Valentina Guarneri, Antonio Frassoldati, Alberto Bottini, Katia Cagossi, Giancarlo Bisagni, Samanta Sarti, Alberto Ravaioli, Luigi Cavanna, Giovanni Giardina, Antonino Musolino, Michael Untch, Laura Orlando, Fabrizio Artioli, C. Boni, Daniele Generali, Patrizia Serra, M. Bagnalasta, Luca Marini, Federico Piacentini, Roberto D’Amico, PierFranco Conte - Journal of Clinical Oncology 2012 cited by 368

  15. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

    Authors: Emilio Bajetta, Irene Floriani, Maria Di Bartolomeo, Roberto Labianca, Alfredo Falcone, Francesco Di Costanzo, G. Comella, D. Amadori, Carmine Pinto, Chiara Carlomagno, D. Nitti, Bruno Daniele, Enrico Mini, Davide Poli, Armando Santoro, Stefania Mosconi, R. Casaretti, C. Boni, G. Pinotti, Paolo Bidoli, Lorenza Landi, Gerardo Rosati, Alessandra Ravaioli, Maurizio Cantore, Francesca Di Fabio, Enrico Aitini, Alberto Marchet, Irene Floriani, Eliana Rulli, M. Cropalato Di Tullio, Davide Poli, Francesca Galli, Elena Biagioli, Irene De Simone, Davide Poli, S. Mangano, Maurizio Tonato, Emanuele Zucca, Maria Grazia Valsecchi, Irene Floriani, Emilio Bajetta, Maria Di Bartolomeo, Roberto Labianca, D. Amadori, Alfredo Falcone, Francesco Di Costanzo, Bruno Daniele, Carmine Pinto, G. Comella, D. Nitti, Enrico Mini, Sabino De Placido, Alberto Marchet, Emilio Bajetta, Maria Di Bartolomeo, L. Catena, Massimo Schiavo, G. Pinotti, Ilaria Proserpio, Gerardo Rosati, Roberto Bordonaro, S. Cordio, Giovanni Burrafato, Anna Maria Bochicchio, Michele Aieta, Nicola Fazio, Fabio Spada, Vito Amoroso, G Marini, Héctor Soto Parrà, G. Novello, B. Massidda, Maria Teresa Ionta, Mario Comandè, R Venezia, A. Bertolini, E. Menatti, L. Zanlorenzi, Alberto Colombo, A. Iop, Salvatore Bonura, Elena Mazza, Maria Grazia Viganò, A. Ardizzoia, Stefania Dell’Oro, Re G, Davide Adriano Santeufemia, Angela Buonadonna, Dimitri Luisi, G. Ucci, Giuseppe Di Lucca, Andrea Bonetti, Francesca Bergamo, Massimiliano Alù, Francesca Vastola, Paolo Marchetti, D.C. Corsi, Elena Massa, Carmine Pinto, Mary Duro and 122 more - Annals of Oncology 2014 cited by 90

  16. Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group

    Authors: Henning T. Mouridsen, Mikhail Gershanovich, Yan Sun, R. Pérez-Carrión, C. Boni, Alain Monnier, Justus Apffelstaedt, Robert E. Smith, H.P. Sleeboom, F. Jänicke, A Płużańska, Magdolna Dank, D. Becquart, P. P. Bapsy, Eeva Salminen, Ray Snyder, M. Lassus, J. Arnold Verbeek, Beatrix Staffler, Hilary A. Chaudri‐Ross, Margaret Dugan - Journal of Clinical Oncology 2001 cited by 1,016

  17. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

    Authors: Carmelo Bengala, Federica Bertolini, N. Malavasi, C. Boni, Enrico Aitini, Cristina Dealis, S. Zironi, Roberta Depenni, Annalisa Fontana, Cinzia Del Giovane, Gabriele Luppi, PierFranco Conte - British Journal of Cancer 2009 cited by 215

  18. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

    Authors: Tiziana Pressiani, C. Boni, Lorenza Rimassa, Roberto Labianca, S. Fagiuoli, Stefania Salvagni, Dora Ferrari, Enrico Cortesi, Camillo Porta, Claudia Mucciarini, Luciano Latini, Carlo Carnaghi, Maria Banzi, Silvia Fanello, Massimo De Giorgio, Romano Fabio Lutman, G. Torzilli, Maurizio Tommasini, Roberto Ceriani, Giovanni Covini, Maria Chiara Tronconi, Laura Giordano, N. Locopo, S. Naimo, Armando Santoro - Annals of Oncology 2012 cited by 152

  19. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

    Authors: Sergio Bracarda, Roberto Iacovelli, Luca Boni, Mimma Rizzo, Lisa Derosa, Marta Rossi, Luca Galli, Giuseppe Procopio, Michele Sisani, Flavia Longo, Matteo Santoni, Franco Morelli, Giuseppe Di Lorenzo, Amelia Altavilla, Camillo Porta, Andrea Camerini, Bernard Escudier, Angelo Martignetti, Riccardo Ricotta, Donatello Gasparro, Roberto Sabbatini, Giovanni Luca Ceresoli, Alessandra Mosca, Daniele Santini, Claudia Caserta, Luigi Cavanna, Francesco Massari, Teodoro Sava, C. Boni, Elena Verzoni, Giacomo Cartenì, Alketa Hamzaj - Annals of Oncology 2015 cited by 105

  20. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

    Authors: Giorgio V. Scagliotti, Filippo de Marinis, Monica Rinaldi, Lucio Crinò, Cesare Gridelli, Serafino Ricci, Elide Matano, C. Boni, M. Marangolo, Giuseppe Failla, Giuseppe Altavilla, Vincenzo Adamo, A. Ceribelli, M. Clerici, Francesco Di Costanzo, L. Frontini, Maurizio Tonato - Journal of Clinical Oncology 2002 cited by 891

  21. Front‐line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma

    Authors: Vittorio Franciosi, Giorgio Cocconi, Maria Michiara, Francesco Di Costanzo, Vinicio Fosser, Maurizio Tonato, Paolo Carlini, C. Boni, Sofia Di Sarra - Cancer 1999 cited by 240

  22. Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group

    Authors: Jaffer A. Ajani, Vladimir Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla, C. Boni, Adriano Rodrigues, M Fodor, Yee Chao, Э К Возный, Lucile Awad, Eric Van Cutsem - Journal of Clinical Oncology 2007 cited by 182

  23. Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group

    Authors: Jaffer A. Ajani, Vladimir Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla, C. Boni, Adriano Rodrigues, M Fodor, Yee Chao, Э К Возный, Cindy Marabotti, Eric Van Cutsem - Journal of Clinical Oncology 2007 cited by 251

  24. Treatment of Metastatic Malignant Melanoma with Dacarbazine plus Tamoxifen

    Authors: Giorgio Cocconi, Mariangela Bella, F. Calabresi, Maurizio Tonato, R Canaletti, C. Boni, Franco Buzzi, Guido Ceci, E. Corgna, Paolo Costa, Renata Lottici, Franco Papadia, Maria Sofra, M. Bacchi - New England Journal of Medicine 1992 cited by 239